Superoxide dismutase and motor neurone disease/amyotrophic lateral sclerosis
Motor neurone diseaselamyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative condition characterized by muscle weakness and wasting (for a review see [Z] ) which leads to severe disability. There is also spasticity, hyperreflexia, and commonly loss of bulbar function affecting speech and swallowing. The prevalence is approximately 4-10/100 000 with an incidence of 1-2 per 100 000. The main sites affected in the disease are the large motor neurones of spinal cord, motor cortex and brain stem. The lateral corticospinal pyramidal tracts arising from the motor cortex also degenerate giving rise to lateral sclerosis from which the most commonly used term for the disease arises. No cognitive decline normally occurs in this disease although some frontal atrophy may be present in a small proportion of cases. Microscopically, motor neurones of the spinal cord atrophy, undergo chromatolysis, inclusions accumulate (e.g. neurofilament conglomerations, Bunina bodies, Hirano bodies) and spheroids (up to 50pm in diameter) appear, particularly in the proximal axons. In the motor cortex, there is atrophy and loss of Betz cells, and considerable loss of dendritic arborization is evident from Golgi-stained sections. In peripheral nerves, the number of myelinated axons is markedly reduced.
The greatest advance in understanding the aetiology of ALS has come with the discovery of mutations in SODl in a subset of familial cases of ALS. Only 5-10% of cases are familial and only -20% of these familial cases have mutations in SOD1. The remaining gene defects still need to be elucidated.
There are 59 mis-sense mutations known covering all five exons of the gene [3-lo]. Until recently exon 3 was thought to be devoid of mutations as it contributes significantly to the region of the active site. However, we and others have now reported mutations in this exon [ll] . The most common mutation in the U.S.A. (Ala-4Val) which is reported to account for 50% of cases is absent from U.K. studies of over 100 families. In our survey, we detected 13 different mutations in U.K. families, seven of which were novel [9] . Twelve mutations were single-base mis-sense mutations and one was a two-base insertion (Ins132TT) which introduces a premature stop codon and putatively creates a truncated protein. A similar two base deletion has also been reported which generates mRNA of appropriate size but is not accompanied by detectable levels of the truncated protein when expressed in Cosl cells, suggesting that mutant SODl is extremely unstable in mammalian cells [12] . Some codons are apparently 'hot spots' for mutations, e.g. codon 93 which can be transformed from glycine to valine, alanine, serine, aspartate, arginine or cysteine.
Familial ALS (FALS) mutations have been found in all the main functional domains of SOD1, e.g. the electrostatic channel at the active site (Leu-84Va1, Asp-125His, Asn-l39Lys), the Cu binding site (His-46Arg, His-48Gln) and the dimerization interface (Ile-1 12Thr, Ile-l13Thr). Mutations are also found at highly conserved residues, such as five codons which are invariant across multiple species, e.g. Gly-l6Ser, His46Arg, His-48Gln, Leu-106Val and Cys-146Arg.
Large surveys of control populations or other diseases such as Guam Parkinsonldementia complex, Alzheimer's disease or Parkinson's disease where free radical-mediated damage has been implicated have never yielded SOD1 mutations. A small proportion of cases of sporadic ALS have been reported to possess SODl mutations. However, in view of the incomplete penetrance of the disease many of the cases may in fact turn out to be familial. We reported one family in which the disease was present in approximately eight out of 21 individuals in one branch of the family but only one case was present among 12 individuals in the second branch of the family. The obligate carrier had died in his late seventies without manifesting the disease [ 131.
Analysis of SODl enzyme activity in erythrocytes from patients with FALS mutations shows a marked loss of enzyme activity. This generally is of the order of 50% [9] but some mutations only modify enzyme activity by negligible amounts. This reduced enzyme activity is likely to reflect the reduced stability of the enzyme and its more rapid turnover [14] . No correlations have been detected between enzyme activity and disease severity. Even within the same family or within families with the same mutation there is little correlation between enzyme activity and the site of onset, age at onset or duration of disease. In a survey by Cudkowicz et al.
[lo] of 68 families with SODl mutations (out of 366 families), Ala-4Val was found to be the most common mutation (50%, absent in the U.K.). Families with SOD mutations had an earlier age of onset (46.9 years) compared with non-SOD families (50.5 years). Two mutations predicted an earlier age of onset (Gly-37Arg and Leu-38Val) and Ala-4Val predicted shorter survival. Some mutations are well represented in several parts of the world, e.g. Ile-113Thr and Glu-100Gly are found in the U.K., the U.S.A. and Australia whereas others are more localized, e.g. CysdPhe and Val-7Glu to Japan and Asp90Ala to Europe, especially Scandinavia. The latter mutation is required to be homozygous to cause the disease in Finland but in other parts of Europe, a heterozygous presence is associated with disease.
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Over-expression of SOD I and SOD I containing FALS mutations
The functional properties of wild-type SODl and SODl containing FALS mutations have been elucidated using a range of techniques from transfection studies in cell lines to animal models of cerebral ischaemia and transgenic mouse lines. In neural cells, the over-expression of SODl inhibits apoptosis induced by serum withdrawal and growth factor withdrawal or by calcium ionophore. In contrast, over-expression of SODl containing FALS mutations promotes neural apoptosis [15] . These cell lines show reduced viability and are more vulnerable to oxidative stress. SODl down-regulation by use of antisense oligonucleotides causes apoptosis which is reversed by interleukin-1 P-converting enzyme (ICE) inhibitors [16] .
Over-expression of SODl in transgenic mice provides resistance to reperfusion injury after focal cerebral ischaemia and results in greatly reduced infarct volume [ 171. Although overexpression of wild-type SODl never produces motor neurone disease, there is evidence of increased peroxidation. Over-expression of SODl mutations in transgenic mouse lines (e.g. Gly93Ala, Gly-85Arg, Gly-37Arg) provides an excellent model of 'motor neurone disease'. In the first such transgenic line, Gly-93Ala, animals showed motor neurone degeneration, hind limb weakness at 3-4 months of age, loss of large myelinated axons from ventral motor roots and neurofilament accumulation in surviving motor neurones [18] . T h e full profile of ALS pathology
SOD I gene deletion
In Drosophila rnelanogaster the null mutation for SODl confers a syndrome including reduced lifespan, infertility and toxic hypersensitivity to oxygen stress. FALS mutations expected to destabilize SOD 1 subunits and their assembly impair the activity of normal subunits in heterozygotes resulting in significantly lower enzyme activity than expected [20] . The effect of disrupting the interactions responsible for the binding of Cu and Zn at the active site would be the loss of Cu and Zn and the destabilization of the subunit structure. Neurospora crassa mutants null for SODl are sensitive to paraquat and conditions of elevated oxygen [21] .
Deletion of the entire coding region of the SODl gene in mammalian cells is surprisingly free of severe pathology. Development is normal; motor neurone size, density and lipid peroxidation are also all normal. However, motor neurones do appear to be more vulnerable to facial nerve axotomy, showing a 50% loss of motor neurones in animals homozygous for the gene deletion compared with 30% loss in normal animals [22] . In mice bearing a disruption of SODl (either SODl -/-or +/-) there is an exacerbation of neuronal cell injury and oedema formation following cerebral ischaemia [23] .
Gain of function properties demonstrated in SOD I -bearing FALS mutations
The overriding conclusion from these transgenic studies is that the mere loss of SODl enzyme activity in deletion studies is not sufficient to produce severe neuropathology whereas the presence of SODl mutations does produce a motor neurme disease-like condition or exacerbates the effects of cerebral ischaemia. T h e nature of the toxic effect of the mutant protein has been suggested to reside with the observation that SODl enzymes containing FALS mutations also have the property of being able to generate free radicals in addition to their dismutase activity.
Recently it was found that this activity is enhanced in FALS mutants, e.g. Gly-93Ala, whereas dismutase activity is identical to that of the wild-type enzyme [24] . In the U.S.A. the Ala4Val mutation is the most prevalent and also among the most clinically severe having a duration of 1.2 years [lo] . When the cDNA for this SODl mutation was over-expressed in insect cells it was found to have similar dismutase activity to the wild-type enzyme but was found to show even greater free-radical-generating activity than the Gly-93Ala mutant in the presence of low concentrations of HzO2. This was assayed by a spin trap method in which transient free radical generation is detected by conversion to a stable free radical adduct with 5,5 dimethyl-l-pyrroline N-oxide (DMPO) which is detected by EPR spectroscopy. T h e Ala-4Val SOD mutation showed a decreased K,,, for H202 compared with wild-type enzyme which correlated with the clinical severity observed in these patients [25] . Wiedau-Pazos et al. [26] have also shown that several FALS mutations produce higher levels of DMPO-OH adducts compared with the wild-type enzyme. The consequences of the enhanced free radical-generating activity of the FALS mutants could have a direct effect on the SODl enzyme, accelerating the inactivation of the mutant SOD and causing the release of its metal ions, which in turn could promote peroxide generation by the Fenton reaction. In this way the damaging effects would be localized to sites, such as motor neurones, where high concentrations of the mutant enzyme are present.
T h e SODl mutant protein can also generate a nitronium intermediate which nitrates tyrosine [27] and evidence of increased nitrotyrosine residues in ALS spinal cord has been demonstrated.
In order to determine whether SODl mutations give rise to novel protein interactions relevant to ALS pathogenesis which are not shown with wild-type SOD1, the yeast interaction trap system has been used. Two proteins present in ventral spinal cord, lysyl-tRNA synthetase and translocon-associated protein 6 were found to interact with mutant forms of SOD1 but not the wild-type enzyme [28] .
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SOD1 distribution in spinal cord and involvement in ALS pathology
SODl immunoreactivity studies show areas of intense labelling in spinal cord but this seems to be localized mainly to Lewy-body-like hyaline inclusions and spheroids and is not uniformly distributed across motor neurones [29] . Analysis of SODl mRNA in motor neurones of ALS cases shows that although the total number of motor neurones is substantially reduced, the level of expression within preserved cells is normal. However, expression in atrophic neurones is reduced [30] . As is the case for protein levels, the level of SODl mRNA in motor neurones is significantly greater than any other neuronal population emphasizing the potential importance of SOD for the motor neurone. A marked change in levels of SOD is seen between the neonate and young adults. In later adulthood a decrease in SODl appears to develop. We quantified SODl mRNA in control human spinal cord and found a significant age-dependent decline between 26 and 90 years of age (P<O.Ol). This change may be of importance in defining the late onset of the disease in sporadic cases. We also reported abnormal straight-chain filaments in dense tangles in a FALS case with the SODl mutation (Ile-l13Thr), indicating a link between SODl mutations and pathological cytoskeletal changes [311.
Pathogenic mechanisms leading to motor neurone degeneration and the role of SOD1 in this cascade of events A key factor involved in many neurodegenerative events such as those induced by stroke, trauma or seizures is the release of the major excitatory neurotransmitter glutamate. It is present at millimolar concentrations in the central nervous system and readily reaches pathological extracellular concentrations at which it is neurotoxic following such tissue damage. This mechanism has also been implicated in ALS as levels of the glutamate transporter are severely depleted in spinal cord [32] . This could lead to elevated synaptic levels of glutamate. Glutamate is known to lead to a now well-established cascade of reactions that can cause both necrotic and apoptotic cell death. Initially the normal intracellular signalling pathway mediated by Ca2+ is used to induce immediate early genes (IEGs), e.g. c-jun which in turn, when activated, regulate the transcription of other genes. In parallel, cellular 'stress' induces activation of protein kinases which are responsible for activation of transcription by phosphorylation e.g. c-jun N-terminal kinases. T h e IEG c-jun has been shown to play an important role in the central nervous system, in particular with reference to the function of motor neurones in which it is constitutively expressed. c-jun plays a pivotal role in cellular stress as it can promote either repair and recovery or apopotosis. In ALS, we have shown a massive induction of c-jun in ventral spinal cord particularly in neurones of the intermediate grey matter which further implicates this bifurcate pathway in the pathogenic mechanism [33] . Similar changes occur in experimental lesions [34] . The subsequent apoptotic route involves ICE and free-radical-mediated reactions that can be countered by the anti-oxidant properties of bcl-2. In addition, the free-radical-generating reactions of the SODl enzyme containing FALS mutations can potentially promote apoptosis. In support of this model, c-jun was found to be strongly induced in neurones of the intermediate grey matter (Rexed's laminae V-VIII and X) of transgenic mice carrying a FALS mutation (Gly93Ala) [35] .
We are grateful to the Motor Neurone Disease Association, The Hayward Foundation, Smith's Charitable Trust and the Trustees of Charing Cross and Westminster Hospital for their financial support for this research.
